Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Comparing the Short-Term Therapeutic Effects and Safety Profiles of Rituximab Therapy in Pemphigus Vulgaris Patients Either Early Treated or Later Than Six Months Publisher Pubmed



Balighi K1 ; Daneshpazhooh M1 ; Akbari Z1 ; Tavakolpour S2 ; Azimi P3 ; Azizpour A1
Authors

Source: Journal of Dermatological Treatment Published:2019


Abstract

Introduction: Rituximab is a recent treatment in recalcitrant pemphigus vulgaris (PV) patients. This study aims to establish the optimal time for rituximab therapy in PV patients. Methods: In this retrospective study, patients who received rituximab within six months of diagnosis were classified as the early treatment group, and patients who have received it later than six months were classified as the delayed treatment group. Results: Ninety-five PV patients were reviewed. Fourteen (14.8%) and 81 (85.2%) patients received rituximab within the first six-months from diagnosis and after that, respectively. In the former group, seven patients have received rituximab as the first-line therapy. The rate of complete remission off therapy (CR off therapy) was significantly higher in this early treatment group (92.9%) compared with the delayed treatment group (66.6%) (p =.47). The patients in early treated group significantly sooner achieved remission (p <.001) and it lasts for a longer time (p =.006). The relapse rate was also significantly lower in the early treatment group (five patients, 38.5%) compared with the delayed treatment group (54 patients, 71.1%) (p =.02). Conclusions: Early treatment with rituximab can lead to a higher rate of complete remission, a lower rate of disease relapse, and longer duration of complete remission in PV patients. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Related Docs
View other Related Docs
1. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)
2. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients, Journal of Dermatological Treatment (2020)
3. Sixteen-Year History of Rituximab Therapy for 1085 Pemphigus Vulgaris Patients: A Systematic Review, International Immunopharmacology (2018)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (19)
Kamran Balighi (18)
Other Related Docs
4. Updated S2k Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (Eadv), Journal of the European Academy of Dermatology and Venereology (2020)
5. Rituximab Therapy Improves Recalcitrant Pemphigus Vulgaris, EXCLI Journal (2015)
6. Rituximab Exhibits a Better Safety Profile When Used As a First Line of Treatment for Pemphigus Vulgaris: A Retrospective Study, International Immunopharmacology (2021)
7. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)
8. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)
9. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)
10. Comparing Early and Late Treatments With Rituximab in Pemphigus Vulgaris: Which One Is Better?, Archives of Dermatological Research (2019)
11. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab, International Journal of Women's Dermatology (2019)
12. Tofacitinib As the Potent Treatment for Refractory Pemphigus: A Possible Alternative Treatment for Pemphigus, Dermatologic Therapy (2018)
13. Investigating Expression Pattern of Eight Immune-Related Genes in Pemphigus Patients Compared With the Healthy Controls and After Rituximab Therapy: Potential Roles of Ctla4 and Fcgr3a Genes Expression in Outcomes of Rituximab Therapy, Dermatologic Therapy (2020)
14. Immunologic Prediction of Relapse in Patients With Pemphigus Vulgaris (Pv) in Clinical Remission, Journal of the American Academy of Dermatology (2016)
15. Multiple Cycles of Rituximab Therapy for Pemphigus: A Group of Patients With Difficult- To-Treat Disease or a Consequence of Late Rituximab Initiation?, Dermatologic Therapy (2022)
16. Elevated Serum Level of B-Cell Activating Factor (Baff) After Rituximab Therapy in Pemphigus Vulgaris Patients Suggests a Possible Therapeutic Efficacy of B-Cell Depletion Therapies Combined With Anti-Baff Agents, International Journal of Dermatology (2023)
17. Unexpected Worsening of Pemphigus Vulgaris After Rituximab: A Report of Three Cases, International Immunopharmacology (2019)
18. Iranian Guideline for Rituximab Therapy in Pemphigus Patients, Dermatologic Therapy (2019)
19. The Efficacy of Rituximab in Patients With Mucous Membrane Pemphigoid, Journal of Dermatological Treatment (2022)
20. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)